A Non-interventional Study of Diafer (5% Iron Isomaltoside 1000) Administered According to Standard Hospital Practice and Product Labelling in Subjects With Chronic Kidney Disease on Haemodialysis for Treatment of Iron Deficiency

Trial Profile

A Non-interventional Study of Diafer (5% Iron Isomaltoside 1000) Administered According to Standard Hospital Practice and Product Labelling in Subjects With Chronic Kidney Disease on Haemodialysis for Treatment of Iron Deficiency

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Iron isomaltoside 1000 (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Sponsors Pharmacosmos
  • Most Recent Events

    • 13 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 01 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 01 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top